Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS).

[1] In clinical trials of siponimod, the most common adverse effects were headache, high blood pressure, and liver function test abnormalities.

[10] In March 2019, siponimod was approved in the United States to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

[1][13][14] The efficacy of siponimod was shown in a clinical trial[15] of 1,651 patients that compared siponimod to placebo in people with secondary progressive multiple sclerosis who had evidence of disability progression in the prior two years and no relapses in the three months prior to enrollment.

[1] The trial was conducted at 294 centers in Asia, Australia, Canada, Europe, South America, and the United States.